Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Size, Value And Growth Trends Through 2030
The methicillin-resistant staphylococcus aureus (MRSA) testing market size has shown robust expansion in recent years. It is anticipated to increase from $3.95 billion in 2025 to $4.18 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be linked to factors including the rising prevalence of hospital-acquired infections, growing recognition of antibiotic resistance, the development of diagnostic laboratory infrastructure, an increase in hospital infection control programs, and the enhanced application of culture-based diagnostic methods.
The methicillin-resistant staphylococcus aureus (MRSA) testing market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $5.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. Factors driving this growth during the forecast period include the increased uptake of rapid molecular diagnostic technologies, heightened investment in precision medicine and pathogen genomics, the broader implementation of automated laboratory systems, a rising need for real-time infection surveillance, and a more stringent regulatory emphasis on controlling antimicrobial resistance. Key trends observed during the projected timeframe encompass the expanding use of rapid molecular diagnostics to detect antibiotic resistance, the greater deployment of point-of-care MRSA testing within hospitals, the progressive integration of automated microbiology workflows in diagnostic settings, the wider scope of infection surveillance programs across healthcare facilities, and the escalating requirement for multiplex assays dedicated to screening hospital-acquired infections.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=55268413&type=smp
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Expansion Supported By Key Demand Factors
The increasing prevalence of hospital-acquired infections is anticipated to propel the expansion of the methicillin-resistant staphylococcus aureus (MRSA) testing market moving forward. Hospital-acquired infections (HAIs) are secondary illnesses that patients acquire while undergoing medical or surgical treatment within a healthcare facility. This occurrence is escalating globally as the increasing complexity of medical procedures and the substantial number of immunocompromised patients offer more chances for opportunistic pathogens to settle. Methicillin-resistant staphylococcus aureus (mrsa) testing assists in managing these infections by allowing clinicians to identify colonized patients early and implement isolation procedures to prevent transmission throughout the facility. For instance, in August 2025, according to the Health Security Agency, a UK-based national executive agency, the total reported mrsa bacteremia cases reached 81, representing an 8.0% increase compared to 75 cases in August 2024. Therefore, the rising prevalence of hospital-acquired infections is expected to drive the growth of the methicillin-resistant staphylococcus aureus (MRSA) testing market.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Segments: Where Are The Largest Growth Opportunities?
The methicillin-resistant staphylococcus aureus (mrsa) testing market covered in this report is segmented –
1) By Type: Healthcare Acquired Methicillin Resistant Staphylococcus Aureus, Community Acquired Methicillin Resistant Staphylococcus Aureus, Hospital Acquired Methicillin Resistant Staphylococcus Aureus
2) By Indication: Skin And Soft Tissue Infections (SSTIs), Pneumonia, Bloodstream Infections, Surgical And Medical Infections, Other Indications
3) By Technology: Polymerase Chain Reaction (PCR), Real Time Polymerase Chain Reaction (RT-PCR), Chromogenic Media, Enzyme Linked Immunosorbent Assay (ELISA), Other Technologies
4) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Ambulatory Care Centers, Other End Users
Subsegments:
1) By Healthcare Acquired Methicillin Resistant Staphylococcus Aureus: Intensive Care Unit Associated Infections, Catheter Related Infections, Ventilator Associated Infections, Post Surgical Site Infections, Long Term Care Facility Infections
2) By Community Acquired Methicillin Resistant Staphylococcus Aureus: Skin And Soft Tissue Infections, Athlete Associated Infections, Household Transmission Infections, Community Cluster Infections, School And Daycare Associated Infections
3) By Hospital Acquired Methicillin Resistant Staphylococcus Aureus: Surgical Site Infections, Bloodstream Infections, Respiratory Tract Infections, Device Associated Infections, Wound And Burn Infections
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Growth Trends Influencing Competitive Dynamics
Leading companies in the methicillin-resistant staphylococcus aureus (MRSA) testing market are prioritizing the integration of artificial intelligence into their testing methodologies, particularly AI-powered imaging analysis, to secure a competitive advantage. This AI-powered imaging analysis leverages artificial intelligence algorithms to automatically and accurately interpret bacterial growth patterns on chromogenic media plates within MRSA screening workflows. For instance, in May 2023, Becton, Dickinson and Company (BD), a US-based medical technology company, achieved FDA 510(k) clearance for its BD Kiestra MRSA Imaging application. This application automates the inspection of Petri dishes for mauve-colored MRSA colonies, allows for batch review of negative results, and integrates with BD Synapsys Informatics for optimized worklist organization. Laboratories benefit from this technology through decreased turnaround times, reduced staff workload, and the opportunity to redeploy personnel to more complex analyses.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Major Participants And Competitive Dynamics
Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, bioMérieux SA, Hologic Inc., QuidelOrtho Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N. V., Randox Laboratories Ltd., SD Biosensor Inc., Seegene Inc., Hardy Diagnostics Inc., Alifax S. r. l., Ganesh Diagnostic and Imaging Centre Pvt. Ltd., Uniogen Oy, 3B BlackBio Dx Limited, Orange Health Labs Private Limited
Access The Complete Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Report:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the methicillin-resistant staphylococcus aureus (MRSA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (MRSA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.